替罗非班对急性冠脉综合征经皮冠脉介入术后炎症变化的观察  

Observe the effect of tirofiban on serum inflammatory variation with acute coronary syndrome after percutaneous coronary intervention

作　　者：赵林明[1] 邹克勇[1] 刘新红[1] 刘焱[1] 

机构地区：[1]河南大学附属南石医院心内科,473000

出　　处：《中国实用医药》2011年第27期45-46,共2页China Practical Medicine

摘　　要：目的了解替罗非班对急性冠脉综合征(ACS)PCI术后炎症变化的影响。方法将32例ACS患者冠脉造影术后(CAG)随机分为两组,A组(16例)ACS患者CAG术后即刻加用替罗非班。B组(16例)ACS患者CAG术后仅给常规治疗。ACS患者CAG术后应用替罗非班前、PCI术后第1、7天测血清hs-CRP和血清基质金属蛋白酶2的含量。结果替罗非班组(A组)患者较常规治疗组(B组)患者hs-CRP、MMP-2均明显下降(P<0.05)。结论替罗非班能明显降低ACS患者PCI术后血清hs-CRP和MMP-2水平。Objective Research the effect of Tirofiban on serum inflammatory variation with acute coronary syndrome（ACS） after percutaneous coronary intervention（PCI） Methods 32 cases of ACS patients after coronary angiography（CAG）were randomly divided into two groups, group A 16 cases of ACS patients after CAG were added immediately with Tirofiban. Group B 16 cases of ACS patients after CAG were affordeded rou- tine treatment only. With the ACS patients after CAG , after CAG and PCI postoperative 1 days,7 days, hs- CRP and MMP-2 levels were measured. Results Serum hs-CRP, MMP-2 were decreased more significantly in patients treated with additional Tirofiban than in patients treated with routine treatment （ P 〈 0. 05 ）. Conclusion Tirofiban can reduce the serum level of hs-CRP and MMP-2 in the ACS patients after PCI.

关 键 词：替罗非班 超敏C反应蛋白 血清基质金属蛋白酶2 经皮冠脉介入 

分 类 号：R541.4[医药卫生—心血管疾病]